Search Videos and More

Showing 133 - 144 of 605 results

Previous| 1... 11 | 12 | 13 ...51 |Next


Dana-Farber Research News 01.01.2025 News

Dana-Farber Research News 01.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 through December 15.
Turning Up the Heat: Dana-Farber Scientists Describe Key Molecular Shift in Brown Fat Cells News

Turning Up the Heat: Dana-Farber Scientists Describe Key Molecular Shift in Brown Fat Cells

Brown fat is a specialized tissue that has developed a host of important functions over the course of evolution. One of the most critical: the ability to produce heat in response to low temperatures by burning energy.
Ann Partridge, MD, MPH Presents PROs from the COMET Study Video

Ann Partridge, MD, MPH Presents PROs from the COMET Study

Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data.
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study Video

Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study

Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Ada Waks, MD Presents Results of the MARGOT Study Video

Ada Waks, MD Presents Results of the MARGOT Study

Dana-Farber's Ada Waks, MD presented results of MARGOT, a phase 2 trial comparing margetuximab plus chemo or trastuzumab plus chemo in patients with early stage HER2+ breast cancer.
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor Video

Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor

Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Jennifer Ligibel, MD Discusses Weigh Loss Intervention Video

Jennifer Ligibel, MD Discusses Weigh Loss Intervention

Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data. 
Why Zip Code Matters: How Environment Shapes Cancer Risk News

Why Zip Code Matters: How Environment Shapes Cancer Risk

Zip codes didn’t exist until 1963 and were established to help speed the delivery of mail. Today, we rely much less on paper mail but strangely, zip codes play a bigger role.
Dana-Farber Research News 12.15.2024 News

Dana-Farber Research News 12.15.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 through November 30.
Treatment Guideline: Capivasertib Plus Fulvestrant for Advanced Estrogen Receptor-Positive Breast Cancer - Updated in 2025 Document

Treatment Guideline: Capivasertib Plus Fulvestrant for Advanced Estrogen Receptor-Positive Breast Cancer - Updated in 2025

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of capivasertib plus fulvestrant in patients with advanced estrogen receptor-positive breast cancer.
A Vision for Health Equity in Childhood Cancer News

A Vision for Health Equity in Childhood Cancer

The Dana-Farber lab of Kira Bona, MD, MPH, has uncovered an alarming reality: children from low-income households are more likely to experience cancer relapse and face lower survival rates compared to their more privileged peers, despite receiving treatment on highly standardized clinical trials at top academic centers.
Early Detection and Interception Research Shows Promise at ASH News

Early Detection and Interception Research Shows Promise at ASH

Dana-Farber Cancer Institute investigators are leading three separate studies with encouraging results related to the early detection and interception of multiple myeloma.

Showing 133 - 144 of 605 results

Previous| 1... 11 | 12 | 13 ...51 |Next